Keiichi FUKUDA

Keiichi Fukuda, MD/PhD/FACC

Founder and CEO
Professor and Chair, Department of Cardiology, Keio University School of Medicine
    • 1987
    • PhD in Clinical Cardiology, Keio University Graduate School of Medicine
    • 1991
    • Growth Factor Division, National Cancer Center Research Institute
    • 1992
    • Dept of Mol. Medicine, Beth Israel Hospital, Harvard Medical School
    • 1994
    • Cardiovascular Research Center, University of Michigan
    • 1995
    • Lecturer, Department of Cardiology, Keio University School
    • 1999
    • Associate Professor, Institute for Advanced Cardiac Therapeutics, Keio University
    • 2005
    • Professor, Dept of Regenerative Medicine, Keio University
    • 2010
    • Professor, Department of Cardiology, Keio University
    • 2015
    • Founded Heartseed Inc.

Kikuo Yasui

Senior Vice President, Corporate Planning & Business Administration

Mr. Yasui joined Heartseed in 2019 as COO. Before joining Heartseed, he held various positions with increasing responsibilities at AbbVie /Abbott Japan, including Business Unit Manager, Immunology and Group Manager, Market Access. He also worked at Bain. He graduated from the Univ. of Tokyo, Pharmaceutical Sciences. (MSc)

Takehiko Kaneko

Takehiko Kaneko, MD

Senior Vice President, Chief Medical Officer (CMO), Head of R&D

Dr. Takehiko Kaneko has diverse experience in large pharma and small biotech companies, leading R&D organizations and teams. Dr. Kaneko joined Heartseed in 2020 as Chief Medical Officer. Prior to joining Heartseed, He served on the leadership team at SanBio Co. Ltd, where he was responsible for development and regulatory of cell therapy products. He was also engaged in medical affairs at Bristol-Myers Squibb, clinical development at Pfizer, and early development at Novartis. Dr. Kaneko received his medical degree from Keio University School of Medicine.

Yutaro KASAI

Yutaro Kasai

Outside Director

Mr. Kasai founded Heartseed in 2015. He is also the founder and head of Angel Bridge. Before founding Angel Bridge, he worked top-tier Private Equity firms including Unison Capital and Bain Capital. He started his career at Goldman Sachs IBD. He earned MBA at Chicago Univ. He graduated from the Univ of Tokyo, Agricultural Sciences. (MSc)

Toshiharu FURUKAWA

Toshiharu Furukawa, MD/PhD

Outside Director

Dr. Furukawa was appointed as Outsider Director of Heartseed in 2017. He graduated Keio University, School of Medicine and earned PhD. He also graduated Keio Univ, School of Literature. He works as a lawyer at TMI Associates. He is also the member of the House of Councilors from LDP.

Kay Deguchi

Kay Deguchi

Independent Director

Kay Deguchi is Owner/COO of Ochanomizu Orthooedic Clinic and was President at AbbVie Japan. Prior to this, she held senior roles at Bell System 24, Stryker Japan, Stryker Orthopaedics, Johnson & Johnson, GE Plastics and The Disney Store in addition to Bain and Company. Kay studied law at Tokyo University and received an MBA from Harvard Business School, where she gained a distinction.


Tomoyuki Kikugawa

Auditor (full-time)

Mr. Kikugawa was appointed as Auditor (full-time) of Heartseed in 2018. He worked at Anritsu (listed in 1st section of TSE) for over 35 years and held increasing responsibility such as CTO and Director, Full-time audits committee.


Akira Fujiyoshi


Mr. Fujiyoshi joined Heartseed in 2019 as External Auditor & Supervisor with his extensive experience in clinical development of new drugs and research management with Eisai. In his career, he spent 12 years in the US for the new drug development of Alzheimer’s disease. After returning to Japan, he was responsible for investor relations as Director. He was a Member of the Board of Eisai and Member of Audit Committee. He is currently serving as Board Member with Semba Corporation. He graduated from Kyoto University, School of Pharmaceutical Sciences.

Leaders at R&D

Hitoshi Kawamura, PhD

Vice President, R&D

Dr. Kawamura joined Heartseed Inc. as Senior Manager of R&D in Aug. 2018 and now deputy Director of R&D Div. He spent about 25-years in pharmaceutical and biotechnology company , as mainly clinical development leader for several products including gene therapy, cardiovascular medicine and others. Just before joining Heartseed, he led global development product as Japan project leader and had track-record to enroll the patients for clinical trial. In addition, the biotechnology company where he contributed in early stage was successfully in IPO.

Ken-ichi Suzuki, PhD

Director, Scientific Liaison

Dr. Suzuki joined Heartseed in 2019. Before joining Heartseed, he had more than 25 years of experience in drug discovery research in the field of hematology and regenerative medicine at Astellas Pharma Inc. Especially, he has extensive experience in leading discovery and preclinical studies of avatrombopag, an oral active small molecule thrombopoietin receptor agonist, approved by FDA in 2018. He pursues stem cell research since 1998 and led regenerative medicine research at Astellas as a project leader. He received his PhD in Pharmaceutical Science from the University of Chiba and is the delegate of the Japanese Society for Regenerative Medicine.

Nobuyuki Takahashi

Director, Head of Manufacturing

Mr. Takahashi joined Heartseed in 2020. Before joining Heartseed, he had more than 25 years of experience in Japanese pharmaceutical company as mainly CMC development. He has extensive experience in GMP of biotechnology products and he led commercial manufacturing planning for developing products. He received his MBA (Management of Technology) from the Waseda Business School.

Scientific Advisory Boards

Dr. Shunei Kyo

President of the Hospital, Tokyo Metropolitan Geriatric Hospital & Institute Gerontology
    • 1974
    • The University of Tokyo School of Medicine, M.D
    • 1997
    • Professor, Department of Cardiac Surgery, Saitama Medical Center
    • 2008
    • Professor, Department of Therapeutic Strategy for Heart Failure, University of Tokyo

Dr. Minoru Ono

Department of Cardiovascular Surgery & -Department of Cooperative Unit of Medicine and Engineering Research, The University of Tokyo
    • 1987
    • The University of Tokyo School of Medicine, M.D.
    • 1998
    • The University of Tokyo School of Medicine, Ph.D.
    • 2009-present
    • Professor and Chairman, Department of Cardiac Surgery, The University of Tokyo School of Medicine
    • 2013-present
    • Director, Cooperative Unit of Medicine and Engineering Research

Dr. Yuji Shiba

Professor, Interdisciplinary Cluster for Cutting Edge Research, Institute for Biomedical Sciences , Department of Biotechnology and Biomedical Engineering, Shinshu University
    • 1998
    • Shinshu University School of Medicine, M.D.
    • 2007
    • Shinshu University School of Medicine, Ph.D
    • 2014
    • Senior Associate Professor, Shinshu University Department of Biotechnology and Biomedical Engineering
    • 2017
    • Professor, Shinshu University Department of Biotechnology and Biomedical Engineering

Dr. Hideyuki Shimizu

Professor, Keio University, Cardiovascular Surgery
    • 1986
    • Keio University, School of Medicine, M.D.
    • 1990
    • Keio University, Graduate School of Medicine Ph.D
    • 1996
    • University of Alabama at Birmingham, Cardiothoracic Surgery, Clinical Fellow
    • 2006
    • Associate Professor, Keio University, Cardiovascular Surgery
    • 2014
    • Professor, Keio University, Cardiovascular Surgery